Security
Alto Neuroscience Inc. · ANRO
ANRONYSECommon stockCurrentCIK 1999480Updated Oct 4, 2026
ANRO price & chart
Loading TradingView…
NYSE:ANRO on TradingView ↗About the company
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in bipolar depression, major depressive disorder, treatment resistant depression, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.
In the news
Shareholders that lost money on Alto Neuroscience, Inc.(ANRO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More News provided by Levi & Korsinsky, LLP Sep 19, 2025, 08:45 ET Share this article Share to X Share this article Share to X NEW YORK , Sept. 19, 2025 /PRNewswire/ -- Levi & ↗
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
SCHEDULE 13G/A - filed by PERCEPTIVE ADVISORS LLC regarding Alto Neuroscience, Inc.
SCHEDULE 13G/A - filed by Vestal Point Capital, LP regarding Alto Neuroscience, Inc.
SCHEDULE 13G/A - filed by Sirenia Capital Management LP regarding Alto Neuroscience, Inc.
10-Q filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 184,689,000Source | 177,542,000Source | 86,628,000Source |
| Property, Plant and Equipment, NetUSD | 1,872,000Source | 2,666,000Source | 1,106,000Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 176,484,000Source | 168,229,000Source | 82,548,000Source |
| Assets, CurrentUSD | 177,718,000Source | 169,337,000Source | 85,391,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,234,000Source | 1,108,000Source | 2,843,000Source |
| Operating Lease, Right-of-Use AssetUSD | 4,261,000Source | 5,035,000Source | 0Source |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 33,547,000Source | 26,082,000Source | 16,823,000Source |
| Stockholders’ equity: | |||
| Additional Paid in CapitalUSD | 352,751,000Source | 289,954,000Source | 5,372,000Source |
| Retained Earnings (Accumulated Deficit)USD | -201,634,000Source | -138,396,000Source | -76,965,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 22,000Source | -101,000Source | -79,000Source |
| Stockholders' Equity Attributable to ParentUSD | 151,142,000Source | 151,460,000Source | -71,672,000Source |
| Liabilities and EquityUSD | 184,689,000Source | 177,542,000Source | 86,628,000Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 11,325,000Source | 10,008,000Source | 5,610,000Source |
| Operating Lease, Liability, CurrentUSD | 1,151,000Source | 870,000Source | 125,000Source |
| Accounts Payable, CurrentUSD | 1,878,000Source | 1,579,000Source | 1,074,000Source |
| Operating Lease, Liability, NoncurrentUSD | 3,823,000Source | 4,516,000Source | 0Source |
| Additional Financial Items | |||
| Accrued Liabilities, CurrentUSD | 8,862,000Source | 8,429,000Source | 4,536,000Source |
| Long-term Debt, Current MaturitiesUSD | 585,000Source | 0Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 16,172,000Source | 10,254,000Source | 9,861,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation, Depletion and AmortizationUSD | — | 502,000Source | 373,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 8,108,000Source | 7,631,000Source | 2,891,000Source |
| Changes in operating assets and liabilities: | |||
| Increase (Decrease) in Accounts PayableUSD | 221,000Source | 516,000Source | -632,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -51,769,000Source | -47,424,000Source | -33,448,000Source |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -24,000Source | -2,075,000Source | -470,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 24,000Source | 2,075,000Source | 470,000Source |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 60,078,000Source | 135,691,000Source | 68,130,000Source |
| Repayments of Long-term DebtUSD | 10,213,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 8,255,000Source | 86,181,000Source | 34,204,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 176,984,000Source | 168,729,000Source | 82,548,000Source |
| Supplemental disclosure of cash flow information: | |||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 1,660,000Source | 999,000Source | 912,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | -30,000Source | -11,000Source | -8,000Source |
| Additional Financial Items | |||
| Share-based Payment Arrangement, ExpenseUSD | 8,108,000Source | 7,631,000Source | 2,891,000Source |
| DepreciationUSD | 661,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -156,000Source | -52,000Source | -140,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | -681,000Source | — | — |
| General and Administrative ExpenseUSD | 20,745,000Source | 21,614,000Source | 7,518,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | 2,469,000Source | 1,375,000Source | 1,370,000Source |
| Investment Income, InterestUSD | 6,603,000Source | 8,851,000Source | 2,349,000Source |
| Net Income (Loss) Attributable to ParentUSD | -63,238,000Source | -61,431,000Source | -36,305,000Source |
| Nonoperating Income (Expense)USD | 3,126,000Source | 7,179,000Source | 1,504,000Source |
| Operating ExpensesUSD | 66,364,000Source | 68,610,000Source | 37,809,000Source |
| Proceeds from Stock Options ExercisedUSD | 703,000Source | 187,000Source | 181,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Operating Income (Loss)USD | -66,364,000Source | -68,610,000Source | -37,809,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -63,238,000Source | -61,431,000Source | -36,305,000Source |
| Earnings Per Share, BasicUSD per share | -2.19Source | -2.5Source | -9.73Source |
| Earnings Per Share, DilutedUSD per share | -2.19Source | -2.5Source | -9.73Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 28,852,000Source | 24,602,000Source | 3,731,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 28,852,000Source | 24,602,000Source | 3,731,000Source |
| Interest Expense (non-operating)USD | 2,469,000Source | 1,375,000Source | 1,370,000Source |
| Additional Financial Items | |||
| General and Administrative ExpenseUSD | 20,745,000Source | 21,614,000Source | 7,518,000Source |
| Investment Income, InterestUSD | 6,603,000Source | 8,851,000Source | 2,349,000Source |
| Nonoperating Income (Expense)USD | 3,126,000Source | 7,179,000Source | 1,504,000Source |
| Operating ExpensesUSD | 66,364,000Source | 68,610,000Source | 37,809,000Source |
| Research and Development ExpenseUSD | 45,619,000Source | 46,996,000Source | 30,291,000Source |
Offerings
Registration 333-294974
Filing attachments
ex991.htm · SCHEDULE 13G · 2026-07-20
EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigne…
Read attachment ↗tm2610746d1_ex99-1.htm · 8-K · 2026-04-01
EX-99.1 2 tm2610746d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements - In the proof-of-concept study, ALTO-101 did not achieve statistical significance on primary endpoint; signals observed across EEG measures including near-significant improvement in theta-ITC (p=0.052) - - Alto has developed a modified-release, once-daily oral formulation of ALTO-101; the Company plans to ex…
Read attachment ↗tm268876d1_ex4-1.htm · 8-K · 2026-03-16
EX-4.1 2 tm268876d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, …
Read attachment ↗tm268876d1_ex99-1.htm · 8-K · 2026-03-16
EX-99.1 5 tm268876d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Alto Neuroscience Announces $120 Million Private Placement Financing - Financing led by Commodore Capital with participation from new and existing biotech focused investors - - Alto expects to use the proceeds of the financing to support the development of ALTO-207 in Treatment Resistant Depression through a planned Phase 3 study and to a potential NDA submission - Mountain View, Calif., March 16, 2026 - Alto Neuroscience, Inc. (“…
Read attachment ↗tm2529007d1_ex4-1.htm · 8-K · 2025-10-20
EX-4.1 2 tm2529007d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT,…
Read attachment ↗tm2529007d1_ex99-1.htm · 8-K · 2025-10-20
EX-99.1 5 tm2529007d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Alto Neuroscience Announces $50 Million Private Placement Financing - Financing led by Perceptive Advisors with participation from new and existing biotech focused investors - - Alto expects to use the proceeds of this financing to accelerate development of ALTO-207 in Treatment Resistant Depression - Mountain View, Calif., October 20, 2025 - Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical compan…
Read attachment ↗